Mutation interactions of BRAF and TP53 define novel prognostic stratification and therapeutic implications in papillary thyroid carcinoma
By integrating <i>BRAF</i>/<i>TP53</i> status with conventional staging, we establish a mutation-guided framework that may refine risk prediction and inform treatment strategies, bridging molecular heterogeneity with clinical decision-making. This work provides insights for personalizing thyroid cancer management.
Authors
- Liu L (ORCID: https://orcid.org/0000-0001-9234-457X)
- Fang Wei (ORCID: https://orcid.org/0000-0002-2994-0069)
Institutions
- Fourth Affiliated Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3389/fendo.2025.1584618
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00